Fatty Liver Scans Are Changing: Where Velacur Beats FibroScan—and Where It Does Not

Fatty liver disease is no longer a condition that doctors only look for when liver enzymes are high. Many people with excess liver fat have normal blood tests, no pain, and no obvious symptoms. The real concern is not just fat in the liver, but whether that fat is causing inflammation, scarring, and long-term liver damage. That is why non-invasive liver scans have become so important.

For many years, FibroScan has been one of the best-known non-invasive tests for fatty liver and liver fibrosis. More recently, Velacur Scan has entered the picture as another ultrasound-based liver assessment tool. This has created a common question for patients and clinics: Velacur Scan vs FibroScan—which test is better for fatty liver and liver fibrosis?

The honest answer is not as simple as saying one test is always better. Velacur appears to have advantages in measuring liver fat in some head-to-head studies, while FibroScan remains the more established and widely validated test for liver stiffness and fibrosis assessment. The best test depends on what the doctor is trying to measure: liver fat, liver stiffness, fibrosis risk, treatment response, or long-term monitoring.

Before comparing both tests, it helps to understand what these scans are actually measuring.

Many patients use the term “fatty liver” as if it is one fixed diagnosis. In reality, fatty liver disease exists on a spectrum. At one end, there is simple fat accumulation in the liver. At the other end, there may be inflammation, progressive scarring, cirrhosis, and even liver failure or liver cancer.

The newer medical term for non-alcoholic fatty liver disease is metabolic dysfunction-associated steatotic liver disease. It is linked with obesity, diabetes, insulin resistance, high triglycerides, high blood pressure, and other metabolic risk factors. When fat in the liver is accompanied by liver-cell injury and inflammation, it may progress to metabolic dysfunction-associated steatohepatitis, previously called non-alcoholic steatohepatitis.

The most important thing to detect is fibrosis. Fibrosis means scarring. Liver fibrosis develops when repeated injury causes the liver to lay down scar tissue. Early fibrosis may be reversible, but advanced fibrosis can progress to cirrhosis. That is why a good fatty liver test should not only say “fat is present.” It should also help doctors estimate whether there is liver stiffness, fibrosis, or early liver damage. ^[1]

FibroScan is a non-invasive liver elastography test. It uses vibration-controlled transient elastography to measure liver stiffness. The result is usually reported in kilopascals. Higher liver stiffness can suggest more fibrosis, although stiffness can also be affected by inflammation, congestion, bile obstruction, and other conditions.

FibroScan also measures liver fat using a value called controlled attenuation parameter. This is reported in decibels per meter. The controlled attenuation parameter score estimates how much the ultrasound signal is weakened as it passes through the liver, which can reflect fat content.

In simple words, FibroScan gives two main types of information:

It estimates liver stiffness, which helps assess fibrosis or cirrhosis risk.

It estimates liver fat, which helps assess hepatic steatosis or fatty liver.

FibroScan has been used for many years across liver clinics and has a large body of published research. It is quick, painless, does not require needles or sedation, and can usually be completed in a few minutes. Because it is so widely used, many hepatologists are familiar with FibroScan reports and cut-off values. ^{[2] [3]}

Velacur Scan is also a non-invasive liver ultrasound-based test, but it uses a different technology approach. According to the United States Food and Drug Administration clearance document, Velacur is intended to provide estimates of tissue stiffness from shear wave speed measurements, ultrasound attenuation, and Velacur Determined Fat Fraction. The device is used in clinical settings by trained medical professionals and is meant to be used along with other clinical indicators in patients with liver disease, including hepatic steatosis.

Velacur uses shear wave absolute vibro-elastography. In practice, the patient lies down, an activation pad creates gentle mechanical waves, and an ultrasound probe is swept over the liver. The system collects information from a volume of liver tissue and produces measurements related to stiffness and fat content.

Velacur can provide:

• Liver stiffness measurement.
• Ultrasound attenuation measurement.
• Velacur Determined Fat Fraction, a newer measurement designed to estimate liver fat using ultrasound attenuation and backscatter information.

The major selling point of Velacur is that it is a point-of-care ultrasound elastography tool with real-time imaging guidance. In theory, this may help the operator better visualize the liver and collect measurements from a larger or more targeted liver region. ^{[4] [5]}

Both Velacur and FibroScan are non-invasive liver scans. Both are used to assess fatty liver and liver fibrosis. Both can be done in an outpatient setting. Both avoid the discomfort and risk of liver biopsy in many routine situations.

The difference lies in how they obtain and process the measurements.

FibroScan uses vibration-controlled transient elastography and controlled attenuation parameter. It has a long track record, broad clinical acceptance, and extensive validation across chronic liver diseases.

Velacur uses shear wave absolute vibro-elastography and ultrasound-based fat measurements, including attenuation and Velacur Determined Fat Fraction. It is newer, more imaging-based, and designed to capture volumetric liver information with ultrasound guidance.

A practical way to think about it is this: FibroScan is the older, more established non-invasive liver stiffness test, while Velacur is the newer ultrasound elastography platform that may offer stronger fat quantification in certain studies.

This is where Velacur appears especially interesting.

In a 2024 head-to-head study, researchers compared Velacur and FibroScan in adults with metabolic dysfunction-associated steatotic liver disease. The study used magnetic resonance elastography as the reference for fibrosis and magnetic resonance imaging-proton density fat fraction as the reference for liver fat. For detection of liver fat greater than 5 percent, Velacur performed better than FibroScan controlled attenuation parameter. The reported area under the curve was 0.94 for Velacur compared with 0.79 for FibroScan, and the difference was statistically significant. ^[6]

A 2025 biopsy-based study also found that Velacur performed well in assessing steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. In that study, Velacur Determined Fat Fraction outperformed FibroScan controlled attenuation parameter for detecting moderate steatosis in the comparison group. ^[7]

Another study validating Velacur Determined Fat Fraction found strong performance against magnetic resonance imaging-proton density fat fraction, with high accuracy for detecting 5 percent liver fat. ^[8]

So, if the main question is “Which scan is better for measuring liver fat?”, current early evidence suggests that Velacur may have an advantage over FibroScan controlled attenuation parameter. This does not mean FibroScan is poor. FibroScan controlled attenuation parameter is still useful and widely used. But Velacur’s newer fat-measurement approach may be better at identifying and quantifying steatosis, especially when liver fat assessment is the main concern.

For fibrosis, the answer is more balanced.

FibroScan has a long history in liver stiffness measurement. It is widely used for patients with fatty liver disease, viral hepatitis, alcohol-related liver disease, and other chronic liver conditions. Many guidelines and clinical pathways include FibroScan or vibration-controlled transient elastography as a secondary test after blood-based risk assessment. ^[1]

In the 2024 head-to-head study comparing Velacur and FibroScan, the two tests were not statistically different for detecting advanced fibrosis when magnetic resonance elastography was used as the reference standard. The reported area under the curve was 0.95 for Velacur and 0.97 for FibroScan for advanced fibrosis detection. ^[6]

This means that, for advanced fibrosis, Velacur looks promising, but FibroScan remains extremely strong and better established. A small numerical difference in a study does not automatically mean one test is clinically superior, especially when the difference is not statistically significant.

For a patient, this matters because liver fibrosis risk is often the most important part of the fatty liver evaluation. If the scan shows low stiffness, the chance of advanced fibrosis may be lower. If stiffness is high, the doctor may recommend further evaluation, more blood tests, magnetic resonance elastography, or occasionally liver biopsy, depending on the clinical picture.

FibroScan’s biggest advantage is not necessarily that it is always more accurate. Its advantage is history, familiarity, and clinical validation.

FibroScan has been used across many countries and many liver diseases. Doctors are familiar with liver stiffness cut-offs, controlled attenuation parameter ranges, and how results should be interpreted. Many published studies, guidelines, and clinical pathways refer to vibration-controlled transient elastography, which is the technology used by FibroScan.

This matters in real life. A test is not just about the machine. It is also about how confidently doctors can interpret the result, compare it with older reports, and use it in treatment decisions. If a patient has been followed with FibroScan for years, repeating FibroScan may be better for consistency.

FibroScan is also widely available in hepatology centers, gastroenterology clinics, and some diagnostic facilities. In many cities, it may simply be easier to find than Velacur.

Velacur’s biggest advantage is that it is a newer imaging-based liver assessment platform that appears to perform strongly for liver fat detection. It may be particularly useful when the doctor wants a better estimate of steatosis or wants a point-of-care tool with ultrasound visualization.

Velacur’s system is designed to measure liver stiffness and attenuation, and its newer Velacur Determined Fat Fraction combines ultrasound attenuation and backscatter coefficient measurements. This is important because liver fat is not always easy to quantify accurately with conventional ultrasound or older attenuation methods. ^[4]

Velacur also uses an ultrasound sweep technique to collect volumetric measurements. The company describes this as capturing a larger liver volume than transient elastography. In theory, larger sampling and image guidance may help in technically difficult patients, though real-world performance depends on operator training, patient body habitus, and the specific clinical setting. ^[5]

This is a common and important question because fatty liver disease is often linked with obesity, central weight gain, and type 2 diabetes. Body habitus can affect ultrasound-based tests. FibroScan can be more difficult in people with higher body mass index, especially if the wrong probe is used or if the skin-to-liver capsule distance is large. FibroScan has an obesity-specific probe that improves feasibility in many larger patients.

Velacur may also be useful in technically challenging cases because of imaging guidance and deeper volumetric measurement capability, but it is still a newer tool and the amount of long-term independent data is smaller.

So, the practical answer is this: in an overweight or obese patient, the best test is the one that produces a reliable, high-quality scan in that clinic. A technically poor Velacur scan is not better than a technically good FibroScan. A technically poor FibroScan is not better than a technically good Velacur scan. The quality of the measurement matters as much as the brand name.

In many routine cases, non-invasive liver scans reduce the need for liver biopsy. However, they do not completely replace biopsy in every situation.

Liver biopsy can still be needed when the diagnosis is uncertain, when autoimmune liver disease or another liver condition is suspected, when blood tests and imaging do not match, or when a precise diagnosis of steatohepatitis and fibrosis stage is required for treatment decisions.

Velacur and FibroScan can estimate liver fat and stiffness. They cannot directly show liver cells under a microscope. They cannot fully assess ballooning injury, microscopic inflammation, or all patterns of liver disease. That is why doctors interpret these scans along with liver enzymes, platelet count, metabolic risk factors, viral hepatitis tests, alcohol history, medication history, ultrasound findings, and sometimes magnetic resonance imaging.

A common mistake is to look at the number alone and panic. Liver stiffness can rise for reasons other than permanent scarring. Active inflammation, recent alcohol intake, liver congestion from heart problems, biliary obstruction, and even eating before the test may affect results.

For FibroScan, the liver stiffness value is measured in kilopascals. Lower values are generally reassuring, while higher values suggest increasing fibrosis risk. The controlled attenuation parameter score estimates liver fat.

For Velacur, the report may include stiffness, attenuation, and Velacur Determined Fat Fraction, depending on the system and software version used. The doctor should explain what the numbers mean in relation to the patient’s risk profile.

A patient with diabetes, obesity, high triglycerides, and a rising liver stiffness value needs more attention than a patient with mild fatty liver and stable low stiffness. The scan is one part of the story, not the whole story.

For follow-up, consistency is very important. If a patient has already had FibroScan and the clinic is tracking liver stiffness over time, repeating FibroScan may make comparison easier. Switching between technologies may create confusion because the numbers are not always directly interchangeable.

However, if the goal is to monitor liver fat reduction after weight loss, diabetes control, medication, or lifestyle changes, Velacur’s fat-measurement tools may be attractive, especially if the clinic uses the same Velacur system consistently.

The best follow-up test is usually the same high-quality test repeated under similar conditions: fasting state, similar timing, trained operator, and proper interpretation.

If the main concern is detecting or quantifying liver fat, Velacur may have the edge based on recent head-to-head research. Studies comparing Velacur with FibroScan controlled attenuation parameter suggest that Velacur performs better for steatosis detection when magnetic resonance imaging-proton density fat fraction or biopsy is used as the reference standard.

If the main concern is liver fibrosis, FibroScan remains the more established test, with a very large evidence base and broad clinical use. Velacur also appears promising for fibrosis assessment, and available studies suggest it may be comparable to FibroScan for advanced fibrosis, but it does not yet have the same long history of use.

If the question is “Which one should I choose?”, the most realistic answer is:

Choose FibroScan when you want a widely accepted, guideline-familiar, long-established liver stiffness test.

Consider Velacur when liver fat quantification is especially important, when the clinic has strong Velacur experience, or when imaging-guided point-of-care liver assessment is preferred.

Do not choose either test based only on marketing claims. Choose based on the clinical question, scan quality, operator training, availability, and how the doctor will use the result.

Velacur is newer, so its evidence base is still growing. Some Velacur studies include industry involvement or authors affiliated with the device manufacturer. That does not make the studies invalid, but it does mean independent validation over time is important. ^[8]

FibroScan is better established, but it also has limitations. Its fat measurement by controlled attenuation parameter can be affected by technical factors. Liver stiffness can be falsely elevated in certain conditions. Results can be less reliable in some patients with obesity, ascites, narrow rib spaces, or other technical challenges. ^[3]

Neither Velacur nor FibroScan should be read in isolation. A good liver assessment combines scan results with blood tests, clinical risk factors, medical history, and sometimes other imaging.

Velacur Scan may be better for fatty liver fat quantification, based on newer studies showing stronger performance than FibroScan controlled attenuation parameter for detecting steatosis. FibroScan remains the better-established test for liver fibrosis assessment because it has broader validation, more guideline familiarity, and wider clinical use.

For liver fibrosis, current evidence suggests Velacur and FibroScan may be comparable for detecting advanced fibrosis, but FibroScan still has the advantage of a longer track record. For fatty liver detection and fat measurement, Velacur may be the more advanced option, especially with Velacur Determined Fat Fraction.

For most patients, the best test is not simply the newest machine or the most famous machine. The best test is the one that answers the right clinical question with a reliable scan, interpreted by a doctor who understands fatty liver disease, liver stiffness, and fibrosis risk.

Also Read:

• Velacur Liver Scan: How It Detects Fatty Liver, Fibrosis, and Early Liver Damage

References: